Aim: To evaluate Photodynamic therapy (PDT) using Verteporfin (Visudyne) as a line of treatment for submacular choroidal neovascularization (CNV)Design: Prospective, non-comparative, open-label, interventional case series.Subjects: 42 lesions in 41 eyes of 37 patients presented to the outpatient clinic of the Research Institute of Ophthalmology in the period from September 2000 till March 2003. All diagnosed with submacular choroidal neovascularization (CNV) of different etiologies.Methods: Standard Photodynamic therapy using Visudyne, follow-up of vision and fluorescein angiography for a period of 9 months.Main outcome measures: The change in the best-corrected visual acuity (BCVA) and the change in fluorescein leakage from the choroidal neovascular membrane (CNV) at the 9 months follow-up. Also complications were monitored and tabulated.Results: At the end of the 9 months follow-up period, most patients have shown significant benefit from PDT in the form of stability or improvement of vision (71%), on contrast sensitivity (80%) and with the Amsler grid (66%). Myopic patients have shown the highest vision benefit (81%) and age related macular degeneration (AMD) patients have shown a benefit in only (30%). The patients also showed improvement on fluorescein angiography in the form of stoppage, diminution or no change of leakage from the CNV (77%) with decrease in the rate of fluorescein leakage in the still leaking membranes by (88%). Statistically, the smaller the age, in females, the smaller the lesion size regardless of the etiology or type of lesion all have shown a higher benefit from treatment. Only one patient had severe vision loss as she was complicated with ischemic optic neuropathy. Otherwise no serious systemic or local complications were encountered.Conclusion: Photodynamic therapy (PDT) using the Verteporfin (Visudyne) dye has significant benefit in the treatment of submacular choroidal neovascularization of different etiologies.